GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PRA Health Sciences Inc (NAS:PRAH) » Definitions » 3-Year EPS without NRI Growth Rate

PRA Health Sciences (PRA Health Sciences) 3-Year EPS without NRI Growth Rate : 30.90% (As of Mar. 2021)


View and export this data going back to 2014. Start your Free Trial

What is PRA Health Sciences 3-Year EPS without NRI Growth Rate?

PRA Health Sciences's EPS without NRI for the three months ended in Mar. 2021 was $0.86.

During the past 12 months, PRA Health Sciences's average EPS without NRI Growth Rate was -16.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 30.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of PRA Health Sciences was 48.80% per year. The lowest was 19.90% per year. And the median was 30.90% per year.


Competitive Comparison of PRA Health Sciences's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, PRA Health Sciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PRA Health Sciences's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where PRA Health Sciences's 3-Year EPS without NRI Growth Rate falls into.



PRA Health Sciences 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


PRA Health Sciences  (NAS:PRAH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


PRA Health Sciences 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of PRA Health Sciences's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


PRA Health Sciences (PRA Health Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4130 ParkLake Avenue, Suite 400, Raleigh, NC, USA, 27612
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.
Executives
Michael J. Bonello officer: EVP & CFO 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Shannon Colin director, officer: President & CEO PRA INTERNATIONAL 12120 SUNSET HILLS ROAD, SUITE 600 RESTON VA 20190
Christopher L Gaenzle officer: EVP, CAO & General Counsel C/O INC RESEARCH HOLDINGS, INC., 3201 BEECHLEAF COURT, SUITE 600, RALEIGH NC 27604
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Alexander George Dickinson director 31542 CATALINA AVE LAGUNA BEACH CA 92651
Jeffrey T Barber director 6501 WESTON PARKWAY, SUITE 200 CARY NC 27513
Matthew P. Young director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
George R Roberts 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, MENLO PARK CA 94025
Kkr Pra Investors Gp Ii Llc 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors L.p. 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr Pra Investors Gp Llc 10 percent owner 9 WEST 57TH STREET, SUITE 4200 NEW YORK NY 10019
Kkr North America Xi Ltd 10 percent owner KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Kkr North America Fund Xi L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001

PRA Health Sciences (PRA Health Sciences) Headlines

From GuruFocus